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Abstract
RNA interference has a close relationship with the host defense system including adap‐
tive immunity. It is not only involved in regulating immune cells at different stages of the
immune response but also directly induces or enhances antigen presentation and subse‐
quent immune responses. We have previously reported that a small hairpin RNA
(shRNA) targeted the downstream site of a dominant cytotoxic T lymphocyte (CTL) epit‐
ope of human papillomavirus (HPV) type 16 oncogene E7 can stimulate an immune re‐
sponse against E7 expressing tumors in C57BL/6 mice. This results in the elimination of
tumor growth in vivo, whereas an shRNA that targets the upstream site does not. Our re‐
cent data further confirm the long half-life of the 5'-mRNA fragment after shRNA degra‐
dation and its involvement in protein synthesis. This chapter summarizes these findings
and provides some updated explanations for the findings.
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1. Introduction
RNA interference (RNAi) is a conserved gene-regulation mechanism in all eukaryotic cells,
where small RNAs including small interfering RNA (siRNA), small hairpin RNA (shRNA),
and micro-RNA (miRNA, miR) interact with message RNAs (mRNAs) in a sequence-specif‐
ic manner and cause the cleavage or translational blockage of a gene [1, 2]. Because of its
specificity and efficiency, it has been widely utilized as a routine tool for gene functional
studies in biology laboratories worldwide. In addition, since RNAi blockage is very specific
and at the transcriptional level, RNAi-based gene therapy (RNAi therapy) is thought to hold
a great potential for treating many diseases, especially viral infections and genetic disorders.
Synthesized siRNA is thus regarded as a specialized drug for gene therapies. So far, promis‐
ing results have been obtained with RNAi therapy in various diseases and many are being
tested in clinical trials, including viral infections, cancers, and genetic or inflammatory dis‐
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orders [3-7]. As cancers and other emerging diseases such as dementia and super-bug infec‐
tions become major public health issues, RNAi therapy can offer a new solution and has the
additional ability to overcome drug resistances.
Beside the fundamental gene-silencing and gene-regulating roles of RNAi, which will also
regulate the gene functions of immune cells and thus the immune responses, RNAi pathway
itself has an additional function and involvement in inducing adaptive immunity. This func‐
tion has not been well-studied, and the mechanism is not clear. Its relationship with the im‐
mune system in terms of antigen reactivation and antigen presentation is still a new area to
be investigated. Indeed, in plants and primitive species, RNAi is a part of the defense sys‐
tem against viral infections. However, in mammals, RNAi seems not directly involved in the
immune system, probably due to the development of an advanced and sophisticated im‐
mune system. This chapter summarizes the evidence of RNAi-induced immunity against tu‐
mors and provides some updated possible explanations for the findings. The possible link
between miRNA and its degraded products with the immune system has been also dis‐
cussed. Exploring the relationship between RNAi and the immune system may lead to new
discoveries in RNAi biology and approaches for more effective cancer immunotherapy or
treatment for viral and intracellular pathogen infections.
2. The discovery of RNAi-induced adaptive immunity against tumors
In 2009, we reported a discovery about RNAi-induced immunity [7]. We investigated two
shRNAs encoded by lentiviral vectors on their ability to suppress tumor cell growth and
stimulate antitumor immunity in vivo. One shRNA targeted the downstream site of a domi‐
nant cytotoxic T lymphocyte (CTL) epitope of the oncogene E7 of human papillomavirus
(HPV) type 16 (termed downstream shRNA), while another shRNA targeted the upstream
site of this epitope (termed upstream shRNA). Both shRNAs were equally effective at silenc‐
ing E7 gene expression (in mRNA and protein levels) and led to the inhibition of tumor cells
growth in vitro and in vivo [7]. In spite of this, TC1 tumor cells (expressing HPV E6 and E7)
treated with downstream shRNA stimulated an immune response against E7 in C57BL6
mice and resulted in elimination of tumor growth in vivo, whereas cells treated with the up‐
stream shRNA did not. When untreated TC1 tumor cells were injected to the same mice
(challenging tumors), the group of downstream shRNA exhibited a total inhibition of chal‐
lenging tumor growth, whereas no inhibition was observed in the upstream shRNA group.
This ability of downstream shRNA was absent in Rag-/- mice (lack of T- and B-cells), suggest‐
ing adaptive immune response or T-cell response was required. To prove that the immune
response was antigen-specific, we carried out a same animal experiment by immunizing
C57BL/6 mice with TC-1 cells treated with these shRNAs but challenged with another tumor
cell line C2, which has the E7 expression and H-2b genetic background as C57BL/6 mice.
Again, we observed that only mice immunized with downstream shRNA treated cells had a
loss of tumor formation, indicating tumor clearance was specific to E7. Our data indicate
that a more effective treatment can be developed for cervical cancer by combining RNAi
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treatment with immunotherapy. Our results also reveal that RNAi may be widely used as
an antitumor immunity stimulator or enhancer (Fig 1).
Figure 1. Schematic diagram shows RNAi targeting site and 5' mRNA fragment. It is known that in cervical cancer
HPV E7 and mouse lymphoma EG7/OVA (ovalbumin) models, the shRNA targets the downstream site of the CTL
epitope that produce the 5' fragment of mRNA. This makes immature proteins and further induces an immune re‐
sponse.
To prove the applicability of immune response to general tumor antigens, we tested a model
antigen ovalbumin (OVA) expressed in EG7 cells that are a mouse thymoma cell line with
C57BL6 genetic background. We chose the major CTL epitope of OVA, SIINFEKL, as the tar‐
get site and designed two upstream shRNAs OVA-1 and -2 and a downstream shRNA
OVA-3. The shRNA-treated EG7 cells were used to immunize the mice, which were subse‐
quently challenged with untreated EG7 cells. We observed that only mice inoculated with
OVA-3-shRNA treated cells had significantly reduced tumor formation but not with OVA-1
and -2 shRNAs.
3. Confirmation of mRNA fragments and truncated proteins in treated cells
To determine if the RNAi-induced immune response was actually from degraded products
of RNAi, we designed a series of primers that would amplify RNA fragments inside and
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outside the targeting sites of upstream shRNA (E6-1) and downstream shRNA (E7-1, Fig
2A). If an inside fragment was present while the outside fragment was absent, it would indi‐
cate that the mRNA had been cleaved by shRNA at the target site. The cells were treated
with E6-1 and E7-1 shRNAs and incubated for 2–4 days before real-time RT-PCR was car‐
ried out. As expected, the shortest PCR fragment, R3, was observed in all samples (Fig 2B).
The full-length R1 PCR fragment was only observed in untreated TC1 cells or cells infected
with the lentiviral vector control (PLL, Fig 2B). In cells treated with both E7-1 and E6-1, R1
was not found, indicating that shRNA-mediated cleavage was occurring. Of most interest
was the R2 fragment which was found in all samples except cells treated with E6-1. These
results suggest that R2 or R3 short fragments of E6-1 and E7-1 existed in the cells, at least
temporarily at the time we isolated RNA. These short-form mRNAs may act as templates for
short-form proteins (truncated proteins) and trigger antigen presentation to CD8+ T-cells
and a CTL immune response to E7.
Apart from our data, a previous study reported that degradation of the 3' mRNA fragment
resulting from siRNA-mediated cleavage was blocked for some mRNAs, leaving an mRNA
fragment that could act as a template for cDNA synthesis. They suggested that this could
give rise to false negative results and that this phenomenon may be avoided by the careful
design of RT-qPCR primers for each individual siRNA experiment [8]. This report further
confirms that mRNA fragments from RNAi do sometimes exist in the cells. In addition, it
was noticed by researchers that un-degraded fragments of an siRNA-targeted mRNA may
cause false positive effects of microarray analysis [9]. To avoid this, they developed a qRT-
PCR protocol, which allowed for the determination of the optimal time point for mRNA
analyses, indicating mRNA fragments after RNAi can be present in cell for a certain time.
What is the functional role of these mRNA fragments after RNAi? Our data demonstrated
that they can be involved in translational machinery and produce truncated proteins. To ex‐
perimentally prove this, we utilized the OVA-expressing EG7 cell model again. The cells
were treated with downstream and upstream shRNAs and further treated with the protease
inhibitor MG132 to reduce protein degradation before immunoblotting was performed. The
blots were probed with an antibody against the N terminus of OVA protein. The predicted
size of a truncated protein produced by the cleavage of OVA-2 shRNA was 14.7 kDa. We
observed a protein band about 15-kDa in cells treated with the OVA-2 shRNA but not in un‐
treated and OVA-1 or OVA-3 shRNA treated cells. It proves that truncated proteins can be
produced in cells by the translation of mRNA fragment cleaved by shRNA. The predicted
truncated product by shRNA-OVA3 was not observed due to cross-reacting proteins on the
blot [7].
Our recent data (unpublished) showed that the cleaved 5’ and 3’ fragments of human papil‐
lomavirus type 16 (HPV-16) E6/7 mRNA after shRNA treatment were unevenly degraded.
The 5’ mRNA fragment was more abundant and displayed a greater stability than the corre‐
sponding 3’ fragment in the treated cells. Further analysis revealed that the 5’ fragment was
polysome-associated, indicating its active translation, and this was further confirmed by us‐
ing tagged E7 protein to show that C-terminally truncated proteins were produced in treat‐
ed cells (Singhania et al. submitted).
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Figure 2. The shRNA targeting sites and primer design for HPV E6/E7 mRNA (Adapted from Gu et al 2009). (A) The
shRNA and primer sites on E6/E7 mRNA. (B) The PCR products on an agarose gel. Notes: TC1, the untreated cell con‐
trol. PLL, lentiviral vector control. *: indicates the site of CTL epitope. F: forward primer, R: reverse primer.
4. Possible models for explaining RNAi-induced immunity
It is well established that miRNAs play an important role in regulating innate and adaptive
immune responses as a part of their gene-regulating roles. Evidence has accumulated that
miRNAs are involved in the adaptive immune responses by regulating T-cells, B-cells, and
antigen-presenting cells (APCs). For example, miR-214 was reported to target phosphatase
and tensin homolog (PTEN) and increase proliferation and the activation of T-cells [10],
while miR-150, -155, and let-7 have been shown to be involved in the development of T-cells
into memory cells [11]. In addition, miR-184 was shown to inhibit nuclear factor of activated
T-cells-1 (NFAT-1) in the activation of CD4 T-cell in the early stage of adaptive immune re‐
sponses [12] and miR-181-a could promote CD4 and CD8 double positive T-cell develop‐
ment [13]. For B-cells, miR-155 is required for their normal function such as production of
isotype-switched, high-affinity antibodies and for memory responses [14]. It has also been
demonstrated that miR-155 is induced by B-cell receptor (BCR) [15]. However, overexpres‐
sion of miR-155 can immortalize B-cells and lead to transformation, for instance, EBV was
shown to have induced miR-155 expression and transformed B-cells [16, 17]. In addition,
miR-150 is important in B-cell development [18] and so is miR-17 [19, 20].
For dendritic cells (DCs), a recent review summarized the need of miRNAs in their lineage
commitment from bone marrow progenitors and for the development of subsets such as
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plasmacytoid DCs and conventional DCs [21]. Liu et al. (2010) used software to predict and
then conducted experiments to confirm that three members of the miR-148 family,
miR-148a, miR-148b, and miR-152 are negative regulators of the innate immune response
and antigen-presenting capacity of DCs. They showed that miR-148/152 expression was up‐
regulated in DCs on maturation and activation induced by TLR3, TLR4, and TLR9 agonists.
These miRNAs in turn inhibited the production of cytokines including IL-12, IL-6, TNF-al‐
pha, and IFN-beta and upregulation of MHC class II expression and DC-initiated antigen-
specific T-cell proliferation by targeting Calcium/calmodulin-dependent protein kinase II
alpha (CaMKIIα) [22]. In addition, miR-150 and miR-223 has been shown to play an impor‐
tant regulatory role in Langerhans cells (LCs) by cross-presenting a soluble antigen to anti‐
gen-specific CD8(+) T-cells [23, 24]. Beside APCs such as DC and LC, miRNA is shown to be
directly involved in antigen presentation. For example, Bartoszewski et al. (2011) demon‐
strated that the mRNA of human endoplasmic reticulum (ER) antigen peptide transporter 1
(TAP1) is a direct target of miR-346. They showed that the 3'-UTR (un-translational region)
of TAP1 contains a 6-mer seeding region for miR-346 and the ER stress-associated reduction
of TAP1 mRNA and protein levels could be reversed by inhibitory miRNA of miR-346 [25].
As TAP plays an important role in MHC class I-associated antigen presentation, their data
provide an insight for miRNA-regulating MHC class-I-associated antigen presentation dur‐
ing ER stress.
The above-highlighted results clearly indicate miRNA’s regulatory role in many aspects of
adaptive immunity. However, is it possible that miRNA also takes part in host immunity
through mRNA fragments produced after RNAi just like shRNA described in section 2 and
3? Normally, miRNAs target the 3' UTR and lead to the translation block or degradation of
the targeted mRNAs. So when they degrade mRNAs, it is supposed to produce long 5'
mRNA fragments and may also produce truncated proteins. If this is true, the translated de‐
fective proteins could be treated as truncated protein and be processed by proteasome. If
there is a CTL epitope in the defective structure, it could be coupled with the MHC class I
molecule and presented to T-cells by DCs through antigen cross-presentation, as described
above with shRNA. This could be a link between RNAi pathway and antigen presentation
or adaptive immune response.
In the shRNA case discussed above, the target should be at the downstream of a CTL epit‐
ope to induce immunity. When miRNAs target 3' UTR, a site certainly at the downstream
site of any possible CTL epitopes, it is assumed to have the ability to produce truncated pro‐
teins and so to induce immune responses. Therefore, an important question for miRNA biol‐
ogy is whether miRNAs can routinely induce immune responses by degrading mRNA at 3'
UTR and generating 5' mRNA fragments or truncated proteins that contain CTL epitopes?
So far, there is no answer for this question. Another critical question is: what is the differ‐
ence between blocking and degrading mRNA by miRNAs at 3' UTR? Does this relate to an‐
tigen presentation of different proteins?
Because it has been shown that miRNA can act as siRNA and shRNA can be produced in
the same pathway as miRNA [26], it is important and interesting to investigate if miRNA
can induce the same immune response as shRNA. The systems of HPV 16 E7/TC1 and
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OVA/EG7 can be used as good models to investigate this. As miRNAs are routinely transcri‐
bed and involved in interacting with mRNA, this mechanism can be considered as a routine
way in cells to generate CTL containing truncated proteins. However, because most mRNAs
in cells are for self-proteins, their CTL epitopes will not be presented to T-cells. This leaves
the question of whether this is a mechanism just for cells that express viral genes (such as
HPV E7 in TC1 and C2 as above) or for cells expressing foreign genes/antigens (such as
OVA in EG7)? The next question is: can this be generalized to any tumor antigens including
self-antigens? This is an interesting subject to investigate and will facilitate our understand‐
ing of how RNAi pathways interact with and are involved in adaptive immune responses
(antigen presentation) to utilize them for cancer immunotherapy.
Although some miRNA are highly conserved between lower animals and higher animals,
mammals have far more miRNAs compared to nonmammals. This suggests that during evo‐
lution, as gene regulation became so complex and important in higher animals, miRNA or
RNAi pathway gradually specialized into gene regulation. At the same time, as the adaptive
immune system became well developed and highly specialized, these two systems got sepa‐
rated, but as described above, they still have some links. Future investigations leading to in‐
sight into these links will provide answers to the above questions.
5. Conclusion
In summary, RNAi-induced immunity opens a new perspective in which to explore the rela‐
tionship between RNAi pathways and the immune system, especially its involvement in an‐
tigen presentation in the adaptive immune response. For RNAi biology, it will provide an
insight into the understanding of function roles of RNAi (including miRNA and siRNA) in
host defense. In the field of gene therapy for cancers, RNAi can be used as an approach to
silence oncogenes as well as a strategy to enhance immunity against cancer antigens (at least
viral infection related cancers) and further explored as a novel cancer immunotherapy. Fi‐
nally, for intracellar pathogens, it can be used as a strategy for developing new vaccine
through RNAi reactivating their antigens to the immune system.
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